Какова цена за Renascience Inc. (4889)

Цена за Renascience Inc. (4889) Это $8.49

Какова рыночная капитализация для Renascience Inc. (4889)

Рыночная капитализация для Renascience Inc. (4889) Это $117.03M

Renascience Inc. (4889) История Цен

Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached Phase 3 clinical trials for a wide range of indications such as chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets. Another PAI-1 inhibitor, RS5441, is currently in Phase 1 trials for various dermatological conditions. Additionally, RS8001, a water-soluble vitamin, is undergoing Phase 2 clinical development for the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder. Beyond its pharmaceutical ventures, Renascience is also advancing the RS9001 disposable ultrafine endoscope, alongside developing artificial intelligence-driven medical solutions and comprehensive diagnostic tools.

Год	Результативность
2026 (TTM)	2.00%
2025	471.92%
2024	-36.21%
2023	18.40%
2022	-62.92%
2021	0.00%

Год

Результативность

2026 (TTM)

2.00%

2025

471.92%

2024

-36.21%

2023

18.40%

2022

-62.92%

2021

0.00%

Компания	Цена акций	Изменение 1г%	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	$547.71	38.62%	US
Argenx SE ARGX.US	$1.04K	58.06%	NL
Moderna, Inc. MRNA.US	$145.75	437.43%	US
CSL Limited CSL.AX	$118.70	-15.60%	AU
Lonza Group AG LONN.SW	$770.19	8.98%	CH

Компания

Цена акций

Изменение 1г%

Страна